The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Transforming growth factor β (TGF-β) === In normal conditions, alveolar macrophages adhere closely to alveolar epithelial cells, thus inducing the expression of the αvβ6 integrin. Integrins are dimeric cell-surface receptors composed of alpha and beta subunits, which activates TGF-β. TGF-β is a multifunctional cytokine that modulates a variety of biological processes such as cell growth, apoptosis, extracellular matrix synthesis, inflammation, and immune responses. TGF-β tightly regulates anti-inflammatory activity by suppressing pro-inflammatory cytokine production, thereby inhibiting T-lymphocyte function. Integrins avβ6 and avβ8 sequester latent TGF-β to the cell surface, where activation can be tightly coupled to cellular responses to environmental stress in the maintenance of homeostasis; integrins also localize activated TGFβ in the vicinity of the macrophages. Normally mature TGFβ is secreted as a latent complex with its N-terminal fragment, latency-associated peptide (LAP), which inhibits its activity. The latent complex is covalently linked to the extracellular matrix by binding to latent TGF-β-binding proteins. TGF-β is activated by diverse mechanisms in the lung, ultimately involving either proteolysis or conformational alteration of the LAP. αvβ6 integrin is able to mediate activation of TGF-β by binding to TGF-β1 LAP, which serves as a ligand binding site for the integrin, and is an essential component of the TGF-β activation apparatus. Once activated, TGFβ leads to the suppression of macrophage functionality (cytokine production and phagocytosis).
Initial rate experiments. When an enzyme is mixed with a large excess of the substrate, the enzyme-substrate intermediate builds up in a fast initial transient. Then the reaction achieves a steady-state kinetics in which enzyme substrate intermediates remains approximately constant over time and the reaction rate changes relatively slowly. Rates are measured for a short period after the attainment of the quasi-steady state, typically by monitoring the accumulation of product with time. Because the measurements are carried out for a very short period and because of the large excess of substrate, the approximation that the amount of free substrate is approximately equal to the amount of the initial substrate can be made. The initial rate experiment is the simplest to perform and analyze, being relatively free from complications such as back-reaction and enzyme degradation. It is therefore by far the most commonly used type of experiment in enzyme kinetics. Progress curve experiments. In these experiments, the kinetic parameters are determined from expressions for the species concentrations as a function of time. The concentration of the substrate or product is recorded in time after the initial fast transient and for a sufficiently long period to allow the reaction to approach equilibrium. Progress curve experiments were widely used in the early period of enzyme kinetics, but are less common now. Transient kinetics experiments. In these experiments, reaction behaviour is tracked during the initial fast transient as the intermediate reaches the steady-state kinetics period.
Cholesterol is the principal sterol of all animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Cholesterol is biosynthesized by all animal cells and is an essential structural and signaling component of animal cell membranes. In vertebrates, hepatic cells typically produce the greatest amounts of it. In the brain, astrocytes produce cholesterol and transport it to neurons. It is absent among prokaryotes (bacteria and archaea), although there are some exceptions, such as Mycoplasma, which require cholesterol for growth. Cholesterol also serves as a precursor for the biosynthesis of steroid hormones, bile acid, and vitamin D. Elevated levels of cholesterol in the blood, especially when bound to low-density lipoprotein (LDL, often referred to as "bad cholesterol"), may increase the risk of cardiovascular disease. François Poulletier de la Salle first identified cholesterol in solid form in gallstones in 1769. In 1815, chemist Michel Eugène Chevreul named the compound "cholesterine".
In 2007 the British Biochemical Society was given a grant by the Wellcome Trust to catalogue and preserve the 35 laboratory notebooks in which Sanger recorded his research from 1944 to 1983. In reporting this matter, Science noted that Sanger, "the most self-effacing person you could hope to meet", was spending his time gardening at his Cambridgeshire home. Sanger died in his sleep at Addenbrooke's Hospital in Cambridge on 19 November 2013. As noted in his obituary, he had described himself as "just a chap who messed about in a lab", and "academically not brilliant".
Biotechnology encompasses a wide range of procedures for modifying living organisms for human purposes, going back to domestication of animals, the cultivation of plants, and "improvements" to these through breeding programs that employ artificial selection and hybridization. Modern usage also includes genetic engineering, as well as cell and tissue culture technologies. The American Chemical Society defines biotechnology as the application of biological organisms, systems, or processes by various industries to learning about the science of life and the improvement of the value of materials and organisms, such as pharmaceuticals, crops, and livestock. As per the European Federation of Biotechnology, biotechnology is the integration of natural science and organisms, cells, parts thereof, and molecular analogues for products and services. Biotechnology is based on the basic biological sciences (e.g., molecular biology, biochemistry, cell biology, embryology, genetics, microbiology) and conversely provides methods to support and perform basic research in biology.
Sources: en.wikipedia.org
== Neurohypophysial hormones == Neurohypophysial hormones are synthesized in the magnocellular secretory neurons of the hypothalamus. They are then transported along neuronal axons within the infundibular stalk to their axon terminals forming the pars nervosa of the posterior pituitary, where they are stored and released into the systemic circulation. The synthesis, control, and release of those hormones is co-regulated by hormonal, local and synaptic signals. Neurohypophysial hormones include:
In 2008, Calderón signed the Mérida Initiative with the United States, which provided funding, training, and intelligence, and allowed U.S. personnel to operate in Mexico in advisory and intelligence-sharing capacities. By 2011, the Mexican Armed Forces had captured 11,544 people who were believed to have been involved with the cartels and organized crime. In the year prior, 28,000 individuals were arrested on drug-related charges. In October 2012, Mexican Navy forces killed Heriberto Lazcano, leader of Los Zetas, in a shootout in Sabinas, Coahuila, after gunmen attacked their patrol. The operation came just hours after the capture of another senior Zeta, Salvador Alfonso Martínez Escobedo. Lazcano's death is viewed as the most significant cartel leader killing in Calderón's administration. It strengthened the Navy's standing, allowed Miguel Treviño Morales to take control of Los Zetas, and ultimately benefited Joaquín "El Chapo" Guzmán, whose Sinaloa Cartel sought to dominate the Nuevo Laredo smuggling routes.
A negative value of u indicates the presence of heteroatoms in the molecule and a half-integer value of u indicates the presence of an odd number of nitrogen atoms. On addition of heteroatoms, the molecular formula is adjusted by the equivalent mass of carbon and hydrogen. For example, adding N requires removing CH2 and adding O requires removing CH4.
Many firms, like Parcelforce, FedEx and R+L Carriers transport various types of cargo by road, including letters, houses, and cargo containers. Food is commonly transported on roads in order to regularly supply supermarkets with fresh food. Retailers and manufacturers of all kinds use delivery trucks, ranging in size from full semi trucks to smaller delivery vans. Organizations such as the World Bank sometimes use the level of commercial freight transported by smaller businesses as a barometer of healthy economic development.
Sources: en.wikipedia.org
=== Surgical === Gentle surgical technique with careful and meticulous control of bleeding helps avoid seromas. Liposuction contributes to seroma formation when it is done in conjunction with creating a "flap" and potential space is confluent with the treated area. Controversy exists in tummy tuck surgery as to whether electrosurgical dissection either contributes to serum formation or prevents it. Drains are traditionally used, but their use has been challenged by various authors who believe quilting sutures alone may be sufficient to reach results as good as or better than when using drains. Seromas accumulate in what is known as "dead space" where a potential place for the fluid exists. Efforts are directed at reducing or eliminating the dead space. Quilting sutures reduce the risk of the skin–fat layer's separating from the deeper muscle layer, and having the separation fill up with fluid, by physically holding those layers together. Drains suck the two layers together so the body's natural "glue" (fibrin) and wound healing have a chance for a permanent bond.
=== Tire sealant compatibility === There is controversy regarding the compatibility of after-market tire sealants with dTPMS that employ sensors mounted inside the tire. Some manufacturers of sealants assert that their products are indeed compatible, but others warn that the "sealant may come in contact with the sensor in a way that renders the sensor temporarily inoperable until it is properly cleaned, inspected and re-installed by a tire care professional". Such doubts are also reported by others. Use of such sealants may void the TPMS sensor warranty.
== Further reading == Wang, Juan; Li, Yuan Zhi; Chen, Ren Ren; Bao, Jin Yong; Yang, Gong Ming (January 2007). "Comparison of volatiles of banana powder dehydrated by vacuum belt drying, freeze-drying and air-drying". Food Chemistry. 104 (4): 1516. doi:10.1016/j.foodchem.2007.02.029. von Meysenbug, L.; Fine, Archie (May 1936). "Banana powder and the fecal flora of infants". The Journal of Pediatrics. 8 (5): 630. doi:10.1016/S0022-3476(36)80163-2.
A 2025 evidence summary for family physicians concluded that, in people with type 2 diabetes, weekly insulin icodec lowers hemoglobin A1c similarly to daily long-acting insulin glargine or degludec, while noting limited data in people or situations at higher risk for hypoglycemia.
=== Mammalian === Mammalian tyrosinase is a single membrane-spanning transmembrane protein. In humans, tyrosinase is sorted into melanosomes and the catalytically active domain of the protein resides within melanosomes. Only a small, enzymatically inessential part of the protein extends into the cytoplasm of the melanocyte. As opposed to fungal tyrosinase, human tyrosinase is a membrane-bound glycoprotein and has 13% carbohydrate content. The derived TYR allele (rs2733832) is associated with lighter skin pigmentation in human populations. It is most common in Europe, but is also found at lower, moderate frequencies in Central Asia, the Middle East, North Africa, and among the San and Mbuti Pygmies.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.